Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
6.80
-0.05 (-0.73%)
Dec 5, 2025, 4:00 PM EST - Market closed
Nasus Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 0.74 | 0.58 | 0.93 |
| Research & Development | 0.34 | 0.57 | 1.12 |
| Operating Expenses | 1.08 | 1.15 | 2.04 |
| Operating Income | -1.08 | -1.15 | -2.04 |
| Interest Expense | -0.03 | -0.05 | -0.02 |
| Other Non Operating Income (Expenses) | -0 | -0.03 | -0 |
| EBT Excluding Unusual Items | -1.11 | -1.22 | -2.06 |
| Gain (Loss) on Sale of Investments | -0.44 | 0.22 | -0.09 |
| Pretax Income | -1.55 | -1.01 | -2.15 |
| Earnings From Continuing Operations | -1.55 | -1.01 | -2.15 |
| Earnings From Discontinued Operations | 0.02 | -0.05 | 0.44 |
| Net Income | -1.53 | -1.05 | -1.71 |
| Net Income to Common | -1.53 | -1.05 | -1.71 |
| Shares Outstanding (Basic) | 7 | 7 | 7 |
| Shares Outstanding (Diluted) | 7 | 7 | 7 |
| Shares Change (YoY) | -0.43% | 2.44% | - |
| EPS (Basic) | -0.22 | -0.15 | -0.25 |
| EPS (Diluted) | -0.22 | -0.20 | -0.25 |
| EBIT | -1.08 | -1.15 | -2.04 |
Source: S&P Capital IQ. Standard template.
Financial Sources.